The global Intraoperative Imaging Market is predicted to grow at 6.1% CAGR during the forecast period with the market size reaching USD 2.6 billion by 2024.
Various devices, such as handheld c-arms, intraoperative computed tomography, intraoperative magnetic resonance imaging, and intraoperative ultrasound, add greatly to the scale of the market for intraoperative imaging market.
Human Recombinant Insulin Market
Due to the mounting incidence of diabetes and the rising need for human insulin analogues,
the global human recombinant insulin market is growing at a significant rate. Due to
advanced expertise and ability to manufacture continuous insulin delivery during the day,
the industry has seen strong demand for long-acting human insulin in the coming years.
By Product, the market is categorized into rapid-acting, long-acting, short-acting, premixed,
and intermediate-acting. Long-acting human insulin segment is expected to grow at the
fastest rate in the market due to advanced competence and capability to pose constant
insulin delivery during the day.
By Brand, the market is subdivided into Humalog, Lantus, Novolog, Novorapid, Apidra,
Humulin, Novolin, Levemir and others. The Lantus accounted the foremost share in the
human recombinant insulin market. In addition, Levemir and Apidra are expected to grow at
fastest rate in the market.
By Distribution channel, the market is subdivided into hospital pharmacies, online
pharmacies and retail pharmacies. The retail pharmacies accounted the largest share in the
human recombinant insulin market, as it offers extensive range of diabetic products
including over-the-counter and prescription drugs for the diabetic patients.
By application, the market is subdivided into type I diabetes and type II diabetes. The type II
diabetes accounted the largest share in the human recombinant insulin market due to
mounting incidence of type II diabetes.
The key growth drivers for the human recombinant insulin market are increasing the
number of diabetic patients, promising medical reimbursement in developing countries,
increasing risk factors contributing to diabetes, increasing the market supply of generic
human insulin drugs and increasing the demand for human insulin analogues.
The growth of the human recombinant insulin market is also encouraged by the anticipated
patent expiry of major human analogue products, an expanding geriatri